Melanoma is a highly aggressive skin tumor nicknamed "black cancer of the skin" because it originates from the pigment-forming cells (melanocytes). The tumors are prone to invasive growth and early lymphogenic and hematogenic metastasis. Known risk factors are UV radiation, light skin type, the presence of multiple atypical nevi, and a positive family history. Decisive for the course of the disease are a guideline-based diagnosis and therapy. In addition to complete excision of the primary tumor with an adequate safety margin, various systemic therapies are available. These are in particular BRAF-targeted therapy and PD-1-based immune checkpoint therapy. This mini-review does not claim to be exhaustive, but is intended to focus primarily on those aspects of the disease that are currently in clinical and scientific focus, and on which there are new developments to report. In particular, there are new therapeutic regimens for unresectable melanoma and studies of adjuvant treatments, as well as developments in diagnostics.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/ddg.15053 | DOI Listing |
J Fr Ophtalmol
January 2025
Service d'ophtalmologie, hôpital Claude-Huriez, CHU de Lille, rue Michel-Polonowski, Lille, France.
Lancet Oncol
January 2025
Melanoma World Society, HERACLIN Institute for Data Management in Healthcare, Neuenhagen, Germany.
Dermatologie (Heidelb)
January 2025
Univ. Klinik für Dermatologie und Venerologie, Medizinische Universität Graz, Auenbruggerplatz 8, 8010, Graz, Österreich.
Ophthalmologie
December 2024
Klinik für Augenheilkunde, Universitätsklinikum des Saarlandes, Homburg/Saar, Deutschland.
Klin Monbl Augenheilkd
December 2024
Augenklinik, Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!